Cargando…

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees

IMPORTANCE: Expanding treatment for opioid addiction has been recognized as an essential component of a comprehensive national response to the opioid epidemic. The Drug Addiction Treatment Act and its amendments attempted to improve access to treatment by involving office-based physicians in the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Hefei, Hockenberry, Jason M., Pollack, Harold A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324514/ https://www.ncbi.nlm.nih.gov/pubmed/30646185 http://dx.doi.org/10.1001/jamanetworkopen.2018.2943

Ejemplares similares

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine
por: Nguemeni Tiako, Max Jordan, et al.
Publicado: (2020)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
por: Clark, Brinton, et al.
Publicado: (2019)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
por: Duncan, Alexandra, et al.
Publicado: (2020)

Buprenorphine Waiver Attitudes Among Primary Care Providers
por: Lai, Benjamin, et al.
Publicado: (2022)

A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2012)

Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements
por: Nguemeni Tiako, Max Jordan, et al.
Publicado: (2023)

Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs
por: Keshwani, Shailina, et al.
Publicado: (2022)

Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver
por: Lanham, Holly J., et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

CHARACTERIZING HOME AND COMMUNITY-BASED SERVICE ENROLLEES IN MINNESOTA’S MEDICAID WAIVER PROGRAM
por: Blackburn, Justin, et al.
Publicado: (2022)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Lower buprenorphine elimination rate constant is associated with lower opioid use
por: Elarabi, Hesham Farouk, et al.
Publicado: (2022)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees
por: Cochran, Gerald, et al.
Publicado: (2018)

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
por: Herring, Andrew A., et al.
Publicado: (2021)

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
por: D’Onofrio, Gail, et al.
Publicado: (2023)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
por: Chambers, Laura C., et al.
Publicado: (2023)

Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
por: Chen, Annie Y., et al.
Publicado: (2022)

State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees
por: Lindner, Stephan R., et al.
Publicado: (2023)

Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction
por: Moinaddini, Fatemeh, et al.
Publicado: (2022)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes
por: Hirchak, Katherine A., et al.
Publicado: (2022)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
por: Spetz, Joanne, et al.
Publicado: (2022)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
por: Claypool, Anneke L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kvplr6a63eads7p18m1ha6s6qf